Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00624923 · ClinicalTrials.gov registry record · Phase 2
Targeting Inflammation Using Salsalate in CardioVascular Disease
A Phase 2 study of Coronary Artery Disease and Overweight, sponsored by Joslin Diabetes Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 340
- Enrollment target
- 5
- Study locations
NCT00624923: Completed Phase 2 study of Coronary Artery Disease and Overweight, sponsored by Joslin Diabetes Center.
NCT00624923 is a Phase 2 study of Coronary Artery Disease and Overweight that has completed, run by Joslin Diabetes Center. The registered enrollment target is 340 participants, below the 1,285-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (74% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00624923, a Phase 2 study of Coronary Artery Disease and Overweight, has completed, sponsored by Joslin Diabetes Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 340 participants
- Enrollment target
- 5
- Study locations
Study Summary
The hypothesis is that western lifestyle, with sedentary behaviors and caloric excess promote a chronic, subacute inflammatory state that participates in the development and progression of atherosclerosis. We will evaluate the effects of targeting inflammation using the anti-inflammatory drug salsalate, compared to placebo, on coronary artery plaque volume assessed by multi-detector computed tomographic angiography (MDCTA). The TINSAL-CVD study is a randomized, double-masked, placebo-controlled, 2 arm, clinical trial. The purpose of the study is to compare the effect of salsalate or placebo on sub-acute inflammation and coronary plaque, in people with cardiovascular disease. Participants are randomized to active intervention (salsalate) or placebo interventions for a period of 30 months. The primary endpoint is change in plaque volume in the coronary arteries assessed by MDCTA from baseline to 30 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Salsalate
Study Locations (5)
Massachusetts
- Joslin Diabetes Center - Boston
- Heart Center of Metrowest - Framingham
- South Shore Internal Medicine - Milton
- Newton-Wellesley Cardiology - Newton
Maine
- Seacoast Cardiology - York Village
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2008-09 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
What the finished NCT00624923 record still lists
NCT00624923 is an interventional study that assigns participants to a tested intervention. The registered 340 participants enrollment target is mid-sized for trials with a published cap, below the 1,285-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00624923 lists 5 locations in 2 states (Massachusetts, Maine).
Frequently Asked Questions
What is clinical trial NCT00624923 about?
NCT00624923 is a clinical study titled "Targeting Inflammation Using Salsalate in CardioVascular Disease". The hypothesis is that western lifestyle, with sedentary behaviors and caloric excess promote a chronic, subacute inflammatory state that participates in the development and progression of atherosclerosis. We will evaluate the effects of targeting inflammation using the anti-inflammatory drug salsal...
What is the current status of trial NCT00624923?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 340 participants. The study started on 2008-09. Estimated completion is 2016-07.
What conditions does trial NCT00624923 study?
This clinical trial studies the following conditions: Coronary Artery Disease, Overweight.
What interventions are being tested in trial NCT00624923?
The interventions under investigation include: Placebo (DRUG), Salsalate (DRUG).
Who is sponsoring clinical trial NCT00624923?
This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00624923 being conducted?
This trial has 5 study locations across Maine, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00624923's enrollment target sits among peer trials
340 97th of 219 higher than 123 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.
RECRUITING · Phase 2
-
Prevent Cardiac Surgery Associated AKI Trial
RECRUITING · Phase 2
-
Familiarization and Safety Study of PB127 Ultrasound Contrast Agent
COMPLETED · Phase 2
-
MARS - Monitored Atherosclerosis Regression Study
COMPLETED · Phase 2
-
High Ticagrelor Loading Dose in STEMI
COMPLETED · Phase 2
-
TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
- NCT04545424 · 340 participants · Phase 2
Trial of Therapeutic Hypothermia in Patients With ARDS
- NCT04806958 · 340 participants · NA
The PulsePoint Study
- NCT05323409 · 340 participants · NA
Improving Comprehensive Care of Cancer Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia